Sedivention
Develops minimally invasive one-time cryoablation therapy for obesity via balloon catheter
€2.9MSeed
Role not disclosedS
Superangels
Activity from announced rounds
Activity in this selectionEurope · Seed
Superangels is the Munich early-stage investor whose official portfolio identifies Sodex, Sedivention and sci2sci.
Recorded funding activity
Sodex develops construction-site technology. Sedivention develops a cryoablation treatment for obesity, while sci2sci manages research data and lineage. The firm remains distinct from its Growth Fund and unrelated Superangels namesakes.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $3.4M 1 disclosed · full round size, not this investor’s share